Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 2/20 | 0.39 |
| ▸ | CASP3 | P42574 | 2/20 | 0.39 |
| ▸ | TLR2 | O60603 | 2/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.38 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84334 | 0.99 | FURIN (0.40) | FURINCASP3TLR2PTPN1KMT2A | |
| SCHEMBL13044093 | 0.92 | CASP3 (0.45) | FURINCASP3TLR2PTPN1 | |
| SCHEMBL10066102 | 0.92 | CASP3 (0.45) | FURINCASP3TLR2PTPN1 | |
| SCHEMBL29737788 | 0.92 | CASP3 (0.45) | FURINCASP3TLR2PTPN1 | |
| SCHEMBL13830419 | 0.92 | CASP3 (0.45) | FURINCASP3TLR2PTPN1 | |
| SCHEMBL84123 | 0.92 | CASP3 (0.45) | FURINCASP3TLR2PTPN1 | |
| SCHEMBL12944386 | 0.92 | CASP3 (0.45) | FURINCASP3TLR2PTPN1 | |
| SCHEMBL31371875 | 0.92 | CASP3 (0.45) | FURINCASP3TLR2PTPN1 | |
| SCHEMBL22387795 | 0.92 | CASP3 (0.45) | FURINCASP3TLR2PTPN1 | |
| SCHEMBL29407919 | 0.92 | CASP3 (0.45) | FURINCASP3TLR2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250281630-A1 | PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND/OR PREVENTION | TORAY INDUSTRIES, INC. (JP) | 2025-09-11 | — | — | US | disclosed |
| EP-4580754-A1 | AN INTEGRIN ALPHA10 ANTIBODY DRUG CONJUGATE | Targinta AB (SE) | 2025-07-09 | — | — | EP | disclosed |
| EP-4400121-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING CANCER | Toray Industries, Inc. (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-20240100180-A1 | TUMOR-SPECIFIC CLAUDIN 18.2 ANTIBODY-DRUG CONJUGATES | Sotio Biotech A.S. (CZ) | 2024-03-28 | — | — | US | disclosed |
| WO-2024047172-A1 | AN INTEGRIN ALPHA10 ANTIBODY DRUG CONJUGATE | TARGINTA AB (SE) | 2024-03-07 | — | — | WO | disclosed |
| US-20230398232-A1 | Composition and Use of Alternatively Formatted Anti-Mesothelin Antibodies for the Treatment of Cancer | Navrogen, Inc. | 2023-12-14 | — | — | US | disclosed |
| EP-4267194-A1 | TUMOR-SPECIFIC CLAUDIN 18.2 ANTIBODY-DRUG CONJUGATES | SOTIO Biotech a.s. (CZ) | 2023-11-01 | — | — | EP | disclosed |
| CN-116635085-A | Tumor specific claudin 18.2 antibody-drug conjugate | 斯迪安生物技术公司 | 2023-08-22 | — | — | CN | disclosed |
| WO-2023033129-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING CANCER | 東レ株式会社 | 2023-03-09 | — | — | WO | disclosed |
| WO-2022136642-A1 | TUMOR-SPECIFIC CLAUDIN 18.2 ANTIBODY-DRUG CONJUGATES | Sotio Biotech A.S. (CZ) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022122709-A1 | ANTIBODY-DRUG CONJUGATES BASED ON HUMANIZED CLDN18.2 ANTIBODIES | Sotio Biotech A.S. (CZ) | 2022-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240100180-A1 | TUMOR-SPECIFIC CLAUDIN 18.2 ANTIBODY-DRUG CONJUGATES | EPCAM, KRT18, DSC1 | FURIN 4447/4885CASP3 1120/4885TLR2 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.